Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma.
about
Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinomaVitamin D receptor gene polymorphisms in breast and renal cancer: current state and future approaches (review)Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.VEGF spliced variants: possible role of anti-angiogenesis therapy.Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implications.A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.Treating patients with metastatic renal carcinoma: an escape from Phase III.Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma.Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor.Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer.Future perspectives for mTOR inhibitors in renal cell cancer treatment.Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line.The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.The vitamin D receptor gene ApaI polymorphism is associated with increased risk of renal cell carcinoma in Chinese populationGenetic polymorphisms in cyclin D1 are associated with risk of renal cell cancer in the Chinese population.A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.The use of sunitinib in renal cell carcinoma: where are we now?
P2860
Q26863402-9ABACCD7-5728-4F32-BD6D-365134C56C40Q26992050-8A14F2F1-E490-417C-B28F-A4EFA55764ADQ35205445-1A53411E-71FF-4246-90D1-CF87538E53FFQ35369677-BC473E56-7874-4582-B973-4EDD001F61CBQ37236302-21866E4C-9F3A-40FF-9940-A9FBB92DF118Q37809571-6C012D02-C543-4DAB-BD0D-9D8AE9EA63C8Q37898560-F47F6F25-03BB-44E4-807A-C21C2735FAF7Q38030592-1A52FAF0-8C9C-4EE9-B557-F306A72E05E2Q38048822-2B294F9D-94DE-4D9B-8E61-80AB66266EEFQ38110320-1DA9D979-B767-4E78-801D-40E34699D420Q38294622-EBA7AC91-D25C-43F5-B4F8-9CC588A34D86Q38372445-C40951E6-DBEF-496A-B0EB-F4548836E06EQ38656760-4C7A8CDA-34E9-4D6B-B911-774822232487Q39568931-86EE3F74-09F4-42F2-979E-AADFB085CEE3Q41508367-817873A0-88A7-4020-8B76-1FCB29E24C2EQ47137919-6D5363BD-E773-478D-90EB-40F5FF555E4BQ47650946-A4E3447B-7008-4406-A9DE-97CB8708DC04Q48634468-F907745D-5F4F-4AE8-993C-6F8810C48A04
P2860
Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treating the individual: The n ...... ement of renal cell carcinoma.
@en
Treating the individual: The n ...... ement of renal cell carcinoma.
@nl
type
label
Treating the individual: The n ...... ement of renal cell carcinoma.
@en
Treating the individual: The n ...... ement of renal cell carcinoma.
@nl
prefLabel
Treating the individual: The n ...... ement of renal cell carcinoma.
@en
Treating the individual: The n ...... ement of renal cell carcinoma.
@nl
P2093
P1476
Treating the individual: The n ...... ement of renal cell carcinoma.
@en
P2093
Cezary Szczylik
Joaquim Bellmunt
Peter Mulders
P356
10.1016/J.CTRV.2009.09.001
P577
2009-10-09T00:00:00Z